CLOs on the Move

HR Pharmaceuticals

www.hrpharma.com

 
HR Pharmaceuticals, Inc. is a Delaware registered corporation headquartered in York, Pennsylvania. Owner of the two (2) legacy brands of surgical lubricant: Surgilube & HR Lubricating Jelly; the standard in the medical community for over 85 years. Since the inception of HR Pharma in 2008 we have developed a reputation of quality, safety and value; these same principles date back to 1931 of producing quality products that benefit mankind. With Manufacturing Integrity and 100% compliance to ISO 9001:2008, ISO 13485:2003, cGMP requirements and the Orthodox Union, HR® creates value for our customers by continuously delivering safe and effective medical devices, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.hrpharma.com
  • 2600 Eastern Boulevard Suite 201
    York, PA USA 17402
  • Phone: 877.302.1110

Executives

Name Title Contact Details
Chris Wiesman
 General Counsel Profile

Similar Companies

U.M.G.

U.M.G. is a Harrison, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KPI Ultrasound

KPI Ultrasound is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Care Unlimited Inc

Health Care Unlimited Inc is a Mcallen, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

affordable home care agency ca

affordable home care agency ca is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LumiThera

At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.